Category: Coronavirus

Posted on by — 11 Comments

US Supreme Court Blocks New York Governor Andrew Cuomo Coronavirus Limits

andrewcuomo 09142018

the staff of the Ridgewood blog

Washington DC, The U.S. Supreme Court on Wednesday night blocked New York Gov. Andrew Cuomo from reimposing strict attendance caps at worship services in areas hit hard by the novel coronavirus.

The court ruled 5-4 to bar Cuomo from enforcing his Oct. 6 “Cluster Initiative” against houses of worship that sued to challenge the restrictions.

Cuomo’s initiative had created color-coded limits on mass gatherings and business operations, in an effort to stem the outbreak in New York City areas that were experiencing a surge in cases, according to Bloomberg News.

 

Posted on by — 3 Comments

March For Your Rights Rally to Support Small Business

125786975 3692831917435378 3332056990023327044 o
photo of Morris County Surrogate Heather Darling
the staff of the Ridgewood blog
Morristown NJ, on Sunday morning at 10am to 12pm the March For Your Rights peaceful protest was held.  The protests was held for the right  to run your business, go to work and go to school . The message is one of personal responsibility. Organizers asked attendees to please wear your mask and in the Gathering areas as well as along the March route, please wear your masks and practice social distancing to demonstrate that mandates are not required for people to act responsibly.

Continue reading March For Your Rights Rally to Support Small Business

Posted on by — 3 Comments

Researchers Say COVID Reinfections possible but tend to be milder compared to the original infection

the staff of the Ridgewood blog

Ridgewood NJ, according to Johns Hopkins Center for Health Security researchers from the La Jolla Institute for Immunology published (preprint) results from a study on longer-term immunity against SARS-CoV-2 conferred by natural infection. The study evaluated 185 individuals with previous SARS-CoV-2 infection. All participants, and the majority experienced COVID-19 disease but were not hospitalized. Most of the participants provided a single blood sample between 6 and 240 days after symptom onset, with 41 collected at least 6 months after symptom onset. A subset of 38 participants provided multiple samples over a period of several months. The researchers found that antibodies against the spike protein of SARS-CoV-2 were relatively stable and memory B cells were abundant after 6 months, leading to optimism that immunity against the virus could mitigate the risk of severe COVID-19 disease for “many years.”

Continue reading Researchers Say COVID Reinfections possible but tend to be milder compared to the original infection

Posted on by — 1 Comment

University of Oxford-AstraZeneca Coronavirus Vaccine Produces Strong Immune Response in Older Adults

external content.duckduckgo 29

the staff of the Ridgewood blog

University of Oxford , The ChAdOx1 nCov-2019 coronavirus vaccine, developed by teams at the University of Oxford, has been shown to trigger a robust immune response in healthy adults aged 56-69 and those over 70 years of age. The data, published today in The Lancet, suggest that one of the groups most vulnerable to serious illness, and death from COVID-19, could build immunity.

British pharmaceutical giant AstraZeneca, which is working in collaboration with the University of Oxford, has previously said interim data showed their experimental vaccine had produced an immune response in older and younger adults.

Older adults have been shown to be at higher risk from COVID-19 and should be considered to be a priority for immunisation should any effective vaccine be developed for the disease. Reporting on data from a Phase II trial of the ChAdOx1 nCov-2019 vaccine, the authors write that volunteers in the trial demonstrate similar neutralising antibody titres, and T cell responses across all three age groups (18-55, 56-79, and 70+).

Continue reading University of Oxford-AstraZeneca Coronavirus Vaccine Produces Strong Immune Response in Older Adults

Posted on by — 4 Comments

FDA Approves Home Test Kits for COVID

external content.duckduckgo 27

the staff of the Ridgewood blog

Ridgewood NJ, according to Johns Hopkins Center for Health Security the US FDA granted Emergency Use Authorization to the first fully at-home SARS-CoV-2 diagnostic test kit. The Lucira COVID-19 All-In-One Test Kit must be prescribed by a healthcare provider, but it can be performed by individuals at home. The manufacturer recommends that children under 14 years old should have the test performed by a healthcare provider in order to maximize the chances of obtaining a valid result. The kit comes with a nasal swab, a test tube with detection reagents, and a small test machine. Once the used nasal swab is swirled around the test tube for the requisite amount of time, the user inserts the tube into the machine, which will automatically process the sample and provide visual indication of the results. The test kit will light up as positive, negative, or inconclusive results in around 30 minutes.

Posted on by — Leave a comment

Rutgers Recruiting 2,000 Participants for Johnson & Johnson Phase 3 COVID-19 Vaccine Trial

64310182 10156106202320951 9163112232647655424 n

the staff of the Ridgewood blog

New Brunswick NJ, Rutgers University is a clinical trial site for the Janssen Pharmaceutical Companies of Johnson & Johnson’s phase 3 clinical research study to evaluate the safety and efficacy of Janssen’s COVID-19 vaccine candidate.

Continue reading Rutgers Recruiting 2,000 Participants for Johnson & Johnson Phase 3 COVID-19 Vaccine Trial

Posted on by — 8 Comments

Pfizer Says Final data Shows Covid Vaccine is 95% Effective ,Will Submit to FDA in coming ‘days’

Pfizer Logo

the staff of the Ridgewood blog

NEW YORK & MAINZ, Germany,  Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, after conducting the final efficacy analysis in their ongoing Phase 3 study, their mRNA-based COVID-19 vaccine candidate, BNT162b2, met all of the study’s primary efficacy endpoints. Analysis of the data indicates a vaccine efficacy rate of 95% (p<0.0001) in participants without prior SARS-CoV-2 infection (first primary objective) and also in participants with and without prior SARS-CoV-2 infection (second primary objective), in each case measured from 7 days after the second dose. The first primary objective analysis is based on 170 cases of COVID-19, as specified in the study protocol, of which 162 cases of COVID-19 were observed in the placebo group versus 8 cases in the BNT162b2 group. Efficacy was consistent across age, gender, race and ethnicity demographics. The observed efficacy in adults over 65 years of age was over 94%.

Continue reading Pfizer Says Final data Shows Covid Vaccine is 95% Effective ,Will Submit to FDA in coming ‘days’

Posted on by — Leave a comment

Rutgers-Eagleton Poll Claims Four in Ten New Jerseyans Say They Won’t Get COVID-19 Vaccine

v1 220th sm uoiqpifjyk02 1539120930 6714

the satff of the Ridgewood blog

New Brunswick NJ, while polling has produced less than stellar results in the last 20 years , so take this with a grain of salt , according  a recent Rutgers-Eagleton Poll between 36 percent and 47 percent of New Jerseyans say they will “probably” or “definitely” not get vaccinated against COVID-19, with response rates varying depending on how the question is asked, according to the latest Rutgers-Eagleton Poll.

Continue reading Rutgers-Eagleton Poll Claims Four in Ten New Jerseyans Say They Won’t Get COVID-19 Vaccine

Posted on by — 4 Comments

Moderna’s COVID-19 Vaccine 94.5% Effective !

Vaccine in vial with syringe1

the staff of the Ridgewood blog

CAMBRIDGE, Mass.,  Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the independent, NIH-appointed Data Safety Monitoring Board (DSMB) for the Phase 3 study of mRNA-1273, its vaccine candidate against COVID-19, has informed Moderna that the trial has met the statistical criteria pre-specified in the study protocol for efficacy, with a vaccine efficacy of 94.5%. This study, known as the COVE study, enrolled more than 30,000 participants in the U.S. and is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services.

Continue reading Moderna’s COVID-19 Vaccine 94.5% Effective !

Posted on by — 1 Comment

Reader repeats , “New Jersey should have been well prepared to protect patients in nursing homes from the coronavirus. Instead, nearly half of all the state’s coronavirus deaths have been at nursing homes and assisted living facilities.”

external content.duckduckgo 14

“Thank you Assemblyman Robert Auth on behalf of those poor 11 childrens’ families.
The Ridgewood Blog was covering The Wanague Curse for almost two years now and it’s time for MJDOH and its cronies to be held responsible for those poor 11 innocent souls…..
“Considering all the state and federal reports, and recommendations from Murphy’s own administration, New Jersey should have been well prepared to protect patients in nursing homes from the coronavirus. Instead, nearly half of all the state’s coronavirus deaths have been at nursing homes and assisted living facilities.” ”

https://theridgewoodblog.net/the-murphy-administration-ignored-earlier-lessons-as-the-pandemic-spread-in-nursing-homes/

 

Posted on by — Leave a comment

Civilian Defense and Disaster Control Act Requires That Closed Businesses and Services must be Compensated

gov phil murphy nj generic 041518 1523813414516 5330616 ver1.0 640 3601

the staff of the Ridgewood blog

Montville NJ,  State Senator Joe Pennacchio is calling on Governor Murphy to uphold the Civilian Defense and Disaster Control Act often cited by the Governor in shuttering businesses.

Continue reading Civilian Defense and Disaster Control Act Requires That Closed Businesses and Services must be Compensated

Posted on by — 1 Comment

U.S. Food and Drug Administration Grants Emergency Use Authorization for Eli Lilly COVID Antibody Drug

Eli Lilly Corporate Center

the staff of the Ridgewood blog

INDIANAPOLIS  IN, The U.S. Food and Drug Administration (FDA) today granted Emergency Use Authorization (EUA) for Eli Lilly and Company’s (NYSE: LLY) investigational neutralizing antibody bamlanivimab (LY-CoV555) 700 mg. Bamlanivimab is authorized for the treatment of mild to moderate COVID-19 in adults and pediatric patients 12 years and older with a positive COVID-19 test, who are at high risk for progressing to severe COVID-19 and/or hospitalization. Bamlanivimab should be administered as soon as possible after a positive COVID-19 test and within 10 days of symptom onset. The authorization allows for the distribution and emergency use of bamlanivimab, which is administered via a single intravenous infusion.

Continue reading U.S. Food and Drug Administration Grants Emergency Use Authorization for Eli Lilly COVID Antibody Drug

Posted on by — 19 Comments

PFIZER AND BIONTECH ANNOUNCE VACCINE CANDIDATE AGAINST COVID-19 ACHIEVED 90% SUCCESS RATE

external content.duckduckgo 6

Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis

Analysis evaluated 94 confirmed cases of COVID-19 in trial participants

Study enrolled 43,538 participants, with 42% having diverse backgrounds, and no serious safety concerns have been observed; Safety and additional efficacy data continue to be collected

Submission for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) planned for soon after the required safety milestone is achieved, which is currently expected to occur in the third week of November

Clinical trial to continue through to final analysis at 164 confirmed cases in order to collect further data and characterize the vaccine candidate’s performance against other study endpoints

the staff of the Ridgewood blog

Continue reading PFIZER AND BIONTECH ANNOUNCE VACCINE CANDIDATE AGAINST COVID-19 ACHIEVED 90% SUCCESS RATE

Posted on by — 3 Comments

Farmed Minks Capable of Transmitting SARS-CoV-2 to humans

external content.duckduckgo 4
the staff of the Ridgewood blog
Copenhagen Denmark, according to Johns Hopkins Center for Health Security , Danish Prime Minister Mette Frederiksen announced this week that Denmark will cull all mink at farms across the country, including those used for breeding, in order to mitigate the risk of zoonotic transmission of SARS-CoV-2. Mink have been identified as animals capable of transmitting SARS-CoV-2 to humans, and there have been multiple examples of outbreaks among mink populations in Denmark and elsewhere. Mink are bred in Denmark and other countries for their pelts.

Continue reading Farmed Minks Capable of Transmitting SARS-CoV-2 to humans

Posted on by — Leave a comment

ELI LILLY monoclonal antibody treatment for COVID Shows Promise

Eli Lilly Corporate Center
the staff of the Ridgewood blog
Ridgewood NJ, according to Johns Hopkins Center for Health Security , ELI LILLY A recent study published in the New England Journal of Medicine last week reported that convalescent plasma derived monoclonal antibody treatment (LY-CoV555), developed by Eli Lilly, showed clinical benefit in patients. The study found that patients experienced decreased viral loads and severity, and had no serious adverse effects in outpatients. The phase II trial involved outpatients that had mild to moderate COVID-19. A total of 452 patients participated, receiving either low, medium or high concentration of the antibody, or placebo. Researchers measured the change in viral load after 11 days of treatment, and the study has reported on interim findings. Patients receiving the medium dose (2800 mg) had about a 3 fold reduction in viral load. Differences among placebo and treatment groups were non-significant and smaller for both the low and the high dosage categories. However, patients receiving any antibody dose had lower symptom severity as well as lower hospitalization rates than placebo. Additionally, the percentage of adverse events was similar across treatment and placebo groups.

Continue reading ELI LILLY monoclonal antibody treatment for COVID Shows Promise